Alphatec price target lowered to $13 from $16 at Stifel

Stifel lowered the firm's price target on Alphatec to $13 from $16 and keeps a Buy rating on the shares. Concerns over a potential 2026 Surgical revenue guidance cut remain elevated due to difficult comparisons and slowing growth, though stable ASP trends and achievable volume growth support a positive intermediate- to long-term view, the analyst tells investors in a research note.